Vitamin D differentially regulates B7.1 and B7.2 expression on human peripheral blood monocytes

The hormonal active form of vitamin D3, 1,25‐dihydroxyvitamin D3 (1,25(OH)2D3), inhibits (through an unknown mechanism) the ability of monocytes/macrophages to induce T‐cell activation. For T cells to be optimally activated, recognition of antigen/major histocompatibility complexes (MHC) by the T‐ce...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Immunology 1998-10, Vol.95 (2), p.272-277
Hauptverfasser: Clavreul, A, D'hellencourt, C L, Montero-Menei, C, Potron, G, Couez, D
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 277
container_issue 2
container_start_page 272
container_title Immunology
container_volume 95
creator Clavreul, A
D'hellencourt, C L
Montero-Menei, C
Potron, G
Couez, D
description The hormonal active form of vitamin D3, 1,25‐dihydroxyvitamin D3 (1,25(OH)2D3), inhibits (through an unknown mechanism) the ability of monocytes/macrophages to induce T‐cell activation. For T cells to be optimally activated, recognition of antigen/major histocompatibility complexes (MHC) by the T‐cell receptor (TCR) must be accompanied by a second costimulatory signal. Considerable experimental data now suggest that this costimulatory signal is predominantly generated by B7.1 and/or B7.2 molecules, expressed on antigen‐presenting cells (APC), when engaged to their counter‐receptor, CD28, present on T cells. To determine whether the inhibitory effect of 1,25(OH)2D3 on monocytes/macrophages might involve modulation of the expression of B7.1 and B7.2 molecules, we analysed (by flow cytometry) the influence of 1,25(OH)2D3 and an analogue, KH 1060, on the expression of these two molecules at the surface of resting human peripheral blood monocytes. In parallel, we tested the effect of these two agents on human monocyte expression of cell‐surface markers (CD14 and CD4) and antigen‐presenting molecules (MHC class I and MHC class II). Our results showed that both 1,25(OH)2D3 and KH 1060 inhibited the basal expression of B7.2 in a dose‐ and time‐dependent manner, without affecting B7.1. Moreover, these two compounds increased CD14 and reduced MHC class II and CD4 expression. Furthermore, the effect of 1,25(OH)2D3 on B7 molecule expression in combination with lipopolysaccharide (LPS) or cytokines, including interleukin‐10 (IL‐10), interferon‐γ (IFN‐γ) and tumour necrosis factor‐α (TNF‐α), was studied. The 1,25(OH)2D3‐induced B7.2 down‐regulation was still detectable when monocytes were activated by IL‐10, IFN‐γ and TNF‐α but not with LPS. Moreover, the induction of B7.1 by TNF‐α was inhibited by addition of 1,25(OH)2D3. We conclude that the ability of 1,25(OH)2D3 to decrease B7.2 expression on human monocytes might contribute to its inhibitory effect on APC‐dependent T‐cell activation and to its immunosuppressive properties observed in autoimmune diseases and organ transplantation.
doi_str_mv 10.1046/j.1365-2567.1998.00588.x
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1364315</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>35171168</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5608-2f7bac864455f02d96e5483c09ae8e997b6e8a3d733784a17b5d78d1167a626d3</originalsourceid><addsrcrecordid>eNqNUluL1DAUDqKs4-pPEIIPgg-tuTQ3EGF3vezCLL6oryFtT3cytM2YTNeZf2_qDIPui0IgJznf950rQpiSkpJKvl2XlEtRMCFVSY3RJSFC63L3CC1OjsdoQQg1BdNEPEXPUlrnJydCnKEzo1lVablA9rvfusGP-ANufddBhHHrXd_vcYS7qXdbSPgyx8BubGeDYdhtIqTkw4jzWU2DG_EGot-sILoe130ILR7CGJp9Jj9HTzrXJ3hxvM_Rt08fv15dF8svn2-uLpZFIyTRBetU7Rotq0qIjrDWSBCV5g0xDjQYo2oJ2vFWca505aiqRat0S6lUTjLZ8nP0_qC7meoB2iaXkbOxm-gHF_c2OG__9ox-Ze_Cvc3tqjgVWeDNQWD1gHZ9sbTzH2GccGLUPc3Y18dgMfyYIG3t4FMDfe9GCFOyilDClZH_BFIp8tyYysBXD4DrMMUxd8zm8VYsl00ySB9ATQwpRehOeVJi57Ww67kcYefpzzxtf6-F3WXqyz_bcyIe9yD73x38P30P-__WtTe3t9ngvwBjP8Tq</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>199423370</pqid></control><display><type>article</type><title>Vitamin D differentially regulates B7.1 and B7.2 expression on human peripheral blood monocytes</title><source>MEDLINE</source><source>Wiley Online Library</source><source>Wiley Online Library Journals</source><source>PMC (PubMed Central)</source><source>EZB Free E-Journals</source><creator>Clavreul, A ; D'hellencourt, C L ; Montero-Menei, C ; Potron, G ; Couez, D</creator><creatorcontrib>Clavreul, A ; D'hellencourt, C L ; Montero-Menei, C ; Potron, G ; Couez, D</creatorcontrib><description>The hormonal active form of vitamin D3, 1,25‐dihydroxyvitamin D3 (1,25(OH)2D3), inhibits (through an unknown mechanism) the ability of monocytes/macrophages to induce T‐cell activation. For T cells to be optimally activated, recognition of antigen/major histocompatibility complexes (MHC) by the T‐cell receptor (TCR) must be accompanied by a second costimulatory signal. Considerable experimental data now suggest that this costimulatory signal is predominantly generated by B7.1 and/or B7.2 molecules, expressed on antigen‐presenting cells (APC), when engaged to their counter‐receptor, CD28, present on T cells. To determine whether the inhibitory effect of 1,25(OH)2D3 on monocytes/macrophages might involve modulation of the expression of B7.1 and B7.2 molecules, we analysed (by flow cytometry) the influence of 1,25(OH)2D3 and an analogue, KH 1060, on the expression of these two molecules at the surface of resting human peripheral blood monocytes. In parallel, we tested the effect of these two agents on human monocyte expression of cell‐surface markers (CD14 and CD4) and antigen‐presenting molecules (MHC class I and MHC class II). Our results showed that both 1,25(OH)2D3 and KH 1060 inhibited the basal expression of B7.2 in a dose‐ and time‐dependent manner, without affecting B7.1. Moreover, these two compounds increased CD14 and reduced MHC class II and CD4 expression. Furthermore, the effect of 1,25(OH)2D3 on B7 molecule expression in combination with lipopolysaccharide (LPS) or cytokines, including interleukin‐10 (IL‐10), interferon‐γ (IFN‐γ) and tumour necrosis factor‐α (TNF‐α), was studied. The 1,25(OH)2D3‐induced B7.2 down‐regulation was still detectable when monocytes were activated by IL‐10, IFN‐γ and TNF‐α but not with LPS. Moreover, the induction of B7.1 by TNF‐α was inhibited by addition of 1,25(OH)2D3. We conclude that the ability of 1,25(OH)2D3 to decrease B7.2 expression on human monocytes might contribute to its inhibitory effect on APC‐dependent T‐cell activation and to its immunosuppressive properties observed in autoimmune diseases and organ transplantation.</description><identifier>ISSN: 0019-2805</identifier><identifier>EISSN: 1365-2567</identifier><identifier>DOI: 10.1046/j.1365-2567.1998.00588.x</identifier><identifier>PMID: 9824486</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Science Ltd</publisher><subject>Antigen Presentation - drug effects ; Antigens, CD - metabolism ; B7-1 Antigen - metabolism ; B7-2 Antigen ; Calcitriol - analogs &amp; derivatives ; Calcitriol - pharmacology ; CD4 Antigens - metabolism ; Cytokines - pharmacology ; Dose-Response Relationship, Drug ; Flow Cytometry ; Histocompatibility Antigens Class I - metabolism ; Histocompatibility Antigens Class II - metabolism ; Human health and pathology ; Humans ; Immunosuppressive Agents - pharmacology ; Life Sciences ; Lipopolysaccharide Receptors - metabolism ; Lipopolysaccharides - pharmacology ; Membrane Glycoproteins - metabolism ; Monocytes - drug effects ; Monocytes - immunology ; Time Factors</subject><ispartof>Immunology, 1998-10, Vol.95 (2), p.272-277</ispartof><rights>Copyright Blackwell Scientific Publications Ltd. Oct 1998</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5608-2f7bac864455f02d96e5483c09ae8e997b6e8a3d733784a17b5d78d1167a626d3</citedby><orcidid>0000-0002-1373-6987 ; 0000-0002-4477-8282</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1364315/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1364315/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,1411,1427,27901,27902,45551,46808,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9824486$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.univ-reunion.fr/hal-02303097$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Clavreul, A</creatorcontrib><creatorcontrib>D'hellencourt, C L</creatorcontrib><creatorcontrib>Montero-Menei, C</creatorcontrib><creatorcontrib>Potron, G</creatorcontrib><creatorcontrib>Couez, D</creatorcontrib><title>Vitamin D differentially regulates B7.1 and B7.2 expression on human peripheral blood monocytes</title><title>Immunology</title><addtitle>Immunology</addtitle><description>The hormonal active form of vitamin D3, 1,25‐dihydroxyvitamin D3 (1,25(OH)2D3), inhibits (through an unknown mechanism) the ability of monocytes/macrophages to induce T‐cell activation. For T cells to be optimally activated, recognition of antigen/major histocompatibility complexes (MHC) by the T‐cell receptor (TCR) must be accompanied by a second costimulatory signal. Considerable experimental data now suggest that this costimulatory signal is predominantly generated by B7.1 and/or B7.2 molecules, expressed on antigen‐presenting cells (APC), when engaged to their counter‐receptor, CD28, present on T cells. To determine whether the inhibitory effect of 1,25(OH)2D3 on monocytes/macrophages might involve modulation of the expression of B7.1 and B7.2 molecules, we analysed (by flow cytometry) the influence of 1,25(OH)2D3 and an analogue, KH 1060, on the expression of these two molecules at the surface of resting human peripheral blood monocytes. In parallel, we tested the effect of these two agents on human monocyte expression of cell‐surface markers (CD14 and CD4) and antigen‐presenting molecules (MHC class I and MHC class II). Our results showed that both 1,25(OH)2D3 and KH 1060 inhibited the basal expression of B7.2 in a dose‐ and time‐dependent manner, without affecting B7.1. Moreover, these two compounds increased CD14 and reduced MHC class II and CD4 expression. Furthermore, the effect of 1,25(OH)2D3 on B7 molecule expression in combination with lipopolysaccharide (LPS) or cytokines, including interleukin‐10 (IL‐10), interferon‐γ (IFN‐γ) and tumour necrosis factor‐α (TNF‐α), was studied. The 1,25(OH)2D3‐induced B7.2 down‐regulation was still detectable when monocytes were activated by IL‐10, IFN‐γ and TNF‐α but not with LPS. Moreover, the induction of B7.1 by TNF‐α was inhibited by addition of 1,25(OH)2D3. We conclude that the ability of 1,25(OH)2D3 to decrease B7.2 expression on human monocytes might contribute to its inhibitory effect on APC‐dependent T‐cell activation and to its immunosuppressive properties observed in autoimmune diseases and organ transplantation.</description><subject>Antigen Presentation - drug effects</subject><subject>Antigens, CD - metabolism</subject><subject>B7-1 Antigen - metabolism</subject><subject>B7-2 Antigen</subject><subject>Calcitriol - analogs &amp; derivatives</subject><subject>Calcitriol - pharmacology</subject><subject>CD4 Antigens - metabolism</subject><subject>Cytokines - pharmacology</subject><subject>Dose-Response Relationship, Drug</subject><subject>Flow Cytometry</subject><subject>Histocompatibility Antigens Class I - metabolism</subject><subject>Histocompatibility Antigens Class II - metabolism</subject><subject>Human health and pathology</subject><subject>Humans</subject><subject>Immunosuppressive Agents - pharmacology</subject><subject>Life Sciences</subject><subject>Lipopolysaccharide Receptors - metabolism</subject><subject>Lipopolysaccharides - pharmacology</subject><subject>Membrane Glycoproteins - metabolism</subject><subject>Monocytes - drug effects</subject><subject>Monocytes - immunology</subject><subject>Time Factors</subject><issn>0019-2805</issn><issn>1365-2567</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNUluL1DAUDqKs4-pPEIIPgg-tuTQ3EGF3vezCLL6oryFtT3cytM2YTNeZf2_qDIPui0IgJznf950rQpiSkpJKvl2XlEtRMCFVSY3RJSFC63L3CC1OjsdoQQg1BdNEPEXPUlrnJydCnKEzo1lVablA9rvfusGP-ANufddBhHHrXd_vcYS7qXdbSPgyx8BubGeDYdhtIqTkw4jzWU2DG_EGot-sILoe130ILR7CGJp9Jj9HTzrXJ3hxvM_Rt08fv15dF8svn2-uLpZFIyTRBetU7Rotq0qIjrDWSBCV5g0xDjQYo2oJ2vFWca505aiqRat0S6lUTjLZ8nP0_qC7meoB2iaXkbOxm-gHF_c2OG__9ox-Ze_Cvc3tqjgVWeDNQWD1gHZ9sbTzH2GccGLUPc3Y18dgMfyYIG3t4FMDfe9GCFOyilDClZH_BFIp8tyYysBXD4DrMMUxd8zm8VYsl00ySB9ATQwpRehOeVJi57Ww67kcYefpzzxtf6-F3WXqyz_bcyIe9yD73x38P30P-__WtTe3t9ngvwBjP8Tq</recordid><startdate>199810</startdate><enddate>199810</enddate><creator>Clavreul, A</creator><creator>D'hellencourt, C L</creator><creator>Montero-Menei, C</creator><creator>Potron, G</creator><creator>Couez, D</creator><general>Blackwell Science Ltd</general><general>Wiley Subscription Services, Inc</general><general>Wiley</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QR</scope><scope>7T5</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope><scope>1XC</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1373-6987</orcidid><orcidid>https://orcid.org/0000-0002-4477-8282</orcidid></search><sort><creationdate>199810</creationdate><title>Vitamin D differentially regulates B7.1 and B7.2 expression on human peripheral blood monocytes</title><author>Clavreul, A ; D'hellencourt, C L ; Montero-Menei, C ; Potron, G ; Couez, D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5608-2f7bac864455f02d96e5483c09ae8e997b6e8a3d733784a17b5d78d1167a626d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Antigen Presentation - drug effects</topic><topic>Antigens, CD - metabolism</topic><topic>B7-1 Antigen - metabolism</topic><topic>B7-2 Antigen</topic><topic>Calcitriol - analogs &amp; derivatives</topic><topic>Calcitriol - pharmacology</topic><topic>CD4 Antigens - metabolism</topic><topic>Cytokines - pharmacology</topic><topic>Dose-Response Relationship, Drug</topic><topic>Flow Cytometry</topic><topic>Histocompatibility Antigens Class I - metabolism</topic><topic>Histocompatibility Antigens Class II - metabolism</topic><topic>Human health and pathology</topic><topic>Humans</topic><topic>Immunosuppressive Agents - pharmacology</topic><topic>Life Sciences</topic><topic>Lipopolysaccharide Receptors - metabolism</topic><topic>Lipopolysaccharides - pharmacology</topic><topic>Membrane Glycoproteins - metabolism</topic><topic>Monocytes - drug effects</topic><topic>Monocytes - immunology</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Clavreul, A</creatorcontrib><creatorcontrib>D'hellencourt, C L</creatorcontrib><creatorcontrib>Montero-Menei, C</creatorcontrib><creatorcontrib>Potron, G</creatorcontrib><creatorcontrib>Couez, D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Chemoreception Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Clavreul, A</au><au>D'hellencourt, C L</au><au>Montero-Menei, C</au><au>Potron, G</au><au>Couez, D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vitamin D differentially regulates B7.1 and B7.2 expression on human peripheral blood monocytes</atitle><jtitle>Immunology</jtitle><addtitle>Immunology</addtitle><date>1998-10</date><risdate>1998</risdate><volume>95</volume><issue>2</issue><spage>272</spage><epage>277</epage><pages>272-277</pages><issn>0019-2805</issn><eissn>1365-2567</eissn><abstract>The hormonal active form of vitamin D3, 1,25‐dihydroxyvitamin D3 (1,25(OH)2D3), inhibits (through an unknown mechanism) the ability of monocytes/macrophages to induce T‐cell activation. For T cells to be optimally activated, recognition of antigen/major histocompatibility complexes (MHC) by the T‐cell receptor (TCR) must be accompanied by a second costimulatory signal. Considerable experimental data now suggest that this costimulatory signal is predominantly generated by B7.1 and/or B7.2 molecules, expressed on antigen‐presenting cells (APC), when engaged to their counter‐receptor, CD28, present on T cells. To determine whether the inhibitory effect of 1,25(OH)2D3 on monocytes/macrophages might involve modulation of the expression of B7.1 and B7.2 molecules, we analysed (by flow cytometry) the influence of 1,25(OH)2D3 and an analogue, KH 1060, on the expression of these two molecules at the surface of resting human peripheral blood monocytes. In parallel, we tested the effect of these two agents on human monocyte expression of cell‐surface markers (CD14 and CD4) and antigen‐presenting molecules (MHC class I and MHC class II). Our results showed that both 1,25(OH)2D3 and KH 1060 inhibited the basal expression of B7.2 in a dose‐ and time‐dependent manner, without affecting B7.1. Moreover, these two compounds increased CD14 and reduced MHC class II and CD4 expression. Furthermore, the effect of 1,25(OH)2D3 on B7 molecule expression in combination with lipopolysaccharide (LPS) or cytokines, including interleukin‐10 (IL‐10), interferon‐γ (IFN‐γ) and tumour necrosis factor‐α (TNF‐α), was studied. The 1,25(OH)2D3‐induced B7.2 down‐regulation was still detectable when monocytes were activated by IL‐10, IFN‐γ and TNF‐α but not with LPS. Moreover, the induction of B7.1 by TNF‐α was inhibited by addition of 1,25(OH)2D3. We conclude that the ability of 1,25(OH)2D3 to decrease B7.2 expression on human monocytes might contribute to its inhibitory effect on APC‐dependent T‐cell activation and to its immunosuppressive properties observed in autoimmune diseases and organ transplantation.</abstract><cop>Oxford, UK</cop><pub>Blackwell Science Ltd</pub><pmid>9824486</pmid><doi>10.1046/j.1365-2567.1998.00588.x</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-1373-6987</orcidid><orcidid>https://orcid.org/0000-0002-4477-8282</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0019-2805
ispartof Immunology, 1998-10, Vol.95 (2), p.272-277
issn 0019-2805
1365-2567
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1364315
source MEDLINE; Wiley Online Library; Wiley Online Library Journals; PMC (PubMed Central); EZB Free E-Journals
subjects Antigen Presentation - drug effects
Antigens, CD - metabolism
B7-1 Antigen - metabolism
B7-2 Antigen
Calcitriol - analogs & derivatives
Calcitriol - pharmacology
CD4 Antigens - metabolism
Cytokines - pharmacology
Dose-Response Relationship, Drug
Flow Cytometry
Histocompatibility Antigens Class I - metabolism
Histocompatibility Antigens Class II - metabolism
Human health and pathology
Humans
Immunosuppressive Agents - pharmacology
Life Sciences
Lipopolysaccharide Receptors - metabolism
Lipopolysaccharides - pharmacology
Membrane Glycoproteins - metabolism
Monocytes - drug effects
Monocytes - immunology
Time Factors
title Vitamin D differentially regulates B7.1 and B7.2 expression on human peripheral blood monocytes
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T17%3A08%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vitamin%20D%20differentially%20regulates%20B7.1%20and%20B7.2%20expression%20on%20human%20peripheral%20blood%20monocytes&rft.jtitle=Immunology&rft.au=Clavreul,%20A&rft.date=1998-10&rft.volume=95&rft.issue=2&rft.spage=272&rft.epage=277&rft.pages=272-277&rft.issn=0019-2805&rft.eissn=1365-2567&rft_id=info:doi/10.1046/j.1365-2567.1998.00588.x&rft_dat=%3Cproquest_pubme%3E35171168%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=199423370&rft_id=info:pmid/9824486&rfr_iscdi=true